Skip to Content
Merck
All Photos(1)

Documents

71400-M

Sigma-Aldrich

Rosetta 2(DE3) Singles Competent Cells - Novagen

Escherichia coli, rod shaped

Synonym(s):

BL21 derivatives

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41106202
NACRES:
NA.81

product name

Rosetta 2(DE3) Singles Competent Cells - Novagen, Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

biological source

Escherichia coli

Quality Level

manufacturer/tradename

Novagen®

storage condition

OK to freeze

growth mode

adherent or suspension

morphology

rod shaped

technique(s)

microbiological culture: suitable

cell transformation

transformation efficiency: >2×106 cfu/μg

shipped in

dry ice

storage temp.

−70°C

General description

Genotype: F-ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
A common method for transformation of DNA plasmids into E. coli is the use of chemically competent cells. Although competent cells can be prepared in the laboratory, greater efficiency, reproducibility, and convenience are achieved using Novagen prepared competent cells. Novagen® Singles Competent Cells are designed for ultimate convenience and reliability in plasmid transformation. Chemically competent cells are prepared using an optimized method. Cells are provided in 50µl volumes, eliminating the need to aliquot, freeze/thaw, or waste partially used vials, saving time and money and ensuring reliable cell performance. To use, simply thaw, add DNA, incubate 5 minutes on ice, heat shock for 30 seconds, place on ice for 2 minutes, and add SOC medium.T7 expression strains are lysogens of bacteriophageDE3, as indicated by the (DE3). These hosts carry achromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in appropriate T7 expression vectors, using IPTG as an inducer.
Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for 7 rare codones (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

Components

•11 rxn or 22 rxnRosetta 2(DE3) Competent Cells

•2 × 2 ml or 4 × 2 mlSOC Medium

•10 µlTest Plasmid

Warning

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

Legal Information

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

WGK

WGK 2


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Fatma Betul Ertem et al.
STAR protocols, 3(1), 101158-101158 (2022-02-24)
The SARS-CoV-2 main protease of (Mpro) is an important target for SARS-CoV-2 related drug repurposing and development studies. Here, we describe the steps for structural characterization of SARS-CoV-2 Mpro, starting from plasmid preparation and protein purification. We detail the steps
Serdar Durdagi et al.
Structure (London, England : 1993), 29(12), 1382-1396 (2021-08-18)
The COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug
Yan Yan et al.
Cell, 185(21), 3913-3930 (2022-10-06)
Although women experience significantly higher tau burden and increased risk for Alzheimer's disease (AD) than men, the underlying mechanism for this vulnerability has not been explained. Here, we demonstrate through in vitro and in vivo models, as well as human AD brain
Naotaka Tsutsumi et al.
Immunity, 54(7), 1405-1416 (2021-07-04)
Epstein-Barr virus (EBV) encodes a G protein-coupled receptor (GPCR) termed BILF1 that is essential for EBV-mediated immunosuppression and oncogenesis. BILF1 couples with inhibitory G protein (Gi), the major intracellular signaling effector for human chemokine receptors, and exhibits constitutive signaling activity;

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service